Crohn's Disease News and Research

Latest Crohn's Disease News and Research

New risk factors associated with inflammatory bowel disease

Health researchers at the Christchurch School of Medicine and Health Sciences, Otago University, have found evidence of new risk factors associated with a debilitating illness called Inflammatory Bowel Disease (IBD).

24 Jun 2004

Crohn's disease and ulcerative colitis patients to rally in Washington

The Crohn's & Colitis Foundation of America (CCFA) is traveling to Washington, DC June 14th-15th to build support for legislation aimed at better understanding, preventing and curing Crohn's disease and ulcerative colitis.

11 Jun 2004

Helminthic therapy, using worm eggs to treat patients with inflammatory bowel disorders

University of Iowa Health Care researchers reported important findings recently at a conference of specialists in New Orleans, La. The findings are from their study of helminthic therapy - using specially prepared worm eggs - to treat patients diagnosed with inflammatory bowel disorders that don't respond to standard treatments.

21 May 2004

Accurate and effective new methods for diagnosis of Inflammatory bowel diseases

Inflammatory bowel diseases collectively cause significant lifestyle sacrifices and suffering and millions of dollars in related health care costs every year, partially due to a lack of effective diagnostic procedures and therapies. In new studies presented today at Digestive Disease Week in New Orleans, researchers show evidence of accurate and effective new methods for diagnosis, as well as improved treatment options, for sufferers of ulcerative colitis and Crohn’s diseases.

19 May 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

Researchers receive almost £1 million in funding for Irritable Bowel Syndrome

Researchers at The University of Nottingham, England have picked up almost £1 million in funding for a number of studies into a painful and distressing bowel condition that will affect up to one in 10 of the population at some time or another.

11 May 2004

500,000 patients have now been treated with REMICADE® worldwide

Centocor, Inc., announced today that more than a half million patients worldwide have now been treated with the anti-TNF agent REMICADE® (infliximab) since it was introduced in the United States five years ago.

21 Apr 2004

New research findings about T-cell transport shed light on immune system

New research findings about T-cell transport shed light on how the normal immune system functions and could have implications in fighting autoimmune and inflammatory diseases, say researchers at University of Texas Southwestern Medical Center, Dallas.

20 Apr 2004

Growth hormones combat Crohn’s disease, cardiac disorders and improve fertility in invitro fertilisation

New treatments for breast cancer, skin and wound healing and obesity will be revealed at an international conference in Cairns, Australia next week.

13 Apr 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004

Researchers isolate gene responsible for Chron's disease

Crohn's disease is an inflammatory bowel disease and its prevalence is increasing in industrialized nations. Existing treatments are considered unsatisfactory, often requiring recurring hospitalization and surgeries.

12 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004

Phase 3 study of drug teduglutide in patients with short bowel syndrome

Teduglutide is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Teduglutide has been shown in animal studies and previous human clinical trials to increase the size and number of these cells, thereby increasing the absorptive surface area of the intestines.

6 Apr 2004